Skip to main content

Advertisement

SpringerLink
Log in

TERT Genetic Mutations as Prognostic Marker in Glioma

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Telomerase reverse transcriptase (TERT) encodes the catalytic subunit of telomerase. The role of TERT in gliomagenesis has been extensively investigated. Since the influence of district, population, sample size, and experimental technology, our analysis, based on published articles, was aimed to obtain an accurate estimation of the relationship between TERT mutations and prognosis of glioma patients. PubMed, Web of science and Google Scholar databases were searched for potential articles. Finally, six studies with 2111 patients were included in the meta-analysis. Heterogeneity was evaluated by I2 statistics and P value. I2 > 50 % and P < 0.05 indicated significant heterogeneity between included studies and random-effects model was used; otherwise, fixed-effects model was used for analysis. The results of meta-analysis was expressed as hazard ratio (HR) and 95 % confidence interval (CI). The pooled results calculated by fixed-effects model suggested that TERT mutations were associated with poor prognosis of glioma patients (HR 1.68, 95 % CI 1.43–1.97). In conclusion, TERT mutations may be associated with shorter survival of glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ostrom QT et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–ii56

    Article  PubMed  PubMed Central  Google Scholar 

  2. Weller M et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403

    Article  PubMed  Google Scholar 

  3. Oike T et al (2013) Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One 8(11):e78943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Giardini MA et al (2014) Telomere and telomerase biology. Prog Mol Biol Transl Sci 125:1–40

    Article  CAS  PubMed  Google Scholar 

  5. Cesare AJ, Reddel RR (2010) Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 11(5):319–330

    Article  CAS  PubMed  Google Scholar 

  6. Kim NW et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015

    Article  CAS  PubMed  Google Scholar 

  7. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33(5):787–791

    Article  CAS  PubMed  Google Scholar 

  8. Tahara H et al (1999) Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18(8):1561–1567

    Article  CAS  PubMed  Google Scholar 

  9. Borah S et al (2015) Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347(6225):1006–1010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Melo M et al (2015) Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? J Clin Oncol 33(6):667–668

    Article  PubMed  Google Scholar 

  11. Cevik D, Yildiz G, Ozturk M (2015) Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol 21(1):311–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ma X et al (2014) Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer 86(3):369–373

    Article  PubMed  Google Scholar 

  13. Griewank KG et al (2014) TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 106(9)

  14. Melo M et al (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Qu Y et al (2014) TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer 135(4):1008–1010

    Article  CAS  PubMed  Google Scholar 

  16. Killela PJ et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5(6):1515–1525

    Article  PubMed  PubMed Central  Google Scholar 

  17. Killela PJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Koelsche C et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126(6):907–915

    Article  CAS  PubMed  Google Scholar 

  19. Arita H et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126(2):267–276

    Article  CAS  PubMed  Google Scholar 

  20. Li G et al (2012) Selected polymorphisms of GSTP1 and TERT were associated with glioma risk in Han Chinese. Cancer Epidemiol 36(6):525–527

    Article  PubMed  Google Scholar 

  21. Simon M et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17(1):45–52

    Article  CAS  PubMed  Google Scholar 

  22. Chen C et al (2014) TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One 9(6):e100297

    Article  PubMed  PubMed Central  Google Scholar 

  23. Labussiere M et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111(10):2024–2032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nonoguchi N et al (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126(6):931–937

    Article  CAS  PubMed  Google Scholar 

  25. Labussiere M et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83(13):1200–1206

    Article  CAS  PubMed  Google Scholar 

  26. Wright WE et al (1996) Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18(2):173–179

    Article  CAS  PubMed  Google Scholar 

  27. Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256(2–6):271–282

    Article  CAS  PubMed  Google Scholar 

  28. Shay JW, Wright WE (2001) Ageing and cancer: the telomere and telomerase connection. Novartis Found Symp 235:116–125, discussion 125–9, 146–9

    Article  CAS  PubMed  Google Scholar 

  29. Cohen SB et al (2007) Protein composition of catalytically active human telomerase from immortal cells. Science 315(5820):1850–1853

    Article  CAS  PubMed  Google Scholar 

  30. Greider CW, Blackburn EH (1987) The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51(6):887–898

    Article  CAS  PubMed  Google Scholar 

  31. Nakamura TM et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277(5328):955–959

    Article  CAS  PubMed  Google Scholar 

  32. Nakayama J et al (1998) Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18(1):65–68

    Article  CAS  PubMed  Google Scholar 

  33. Fujimoto K, Takahashi M (1997) Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem Biophys Res Commun 241(3):775–781

    Article  CAS  PubMed  Google Scholar 

  34. Wu KJ et al (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21(2):220–224

    Article  CAS  PubMed  Google Scholar 

  35. Su J et al (2015) Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol 36(8):6333–6339

    Article  CAS  PubMed  Google Scholar 

  36. Vieira de Castro J et al (2015) Impact of TGF-beta1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis. Tumour Biol

  37. Sun G et al (2015) Decreased expression of miR-15b in human gliomas is associated with poor prognosis. Cancer Biother Radiopharm 30(4):169–173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yeung YT et al (2013) Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 168(3):591–606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shan Y et al (2015) Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med 8(6):9114–9120

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ichimura K (2012) Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29(3):131–139

    Article  CAS  PubMed  Google Scholar 

  41. Mosrati MA et al (2015) TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 6(18):16663–16673

    Article  PubMed  PubMed Central  Google Scholar 

  42. Park CK et al (2014) Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget 5(10):3399–3407

    Article  PubMed  PubMed Central  Google Scholar 

  43. Spiegl-Kreinecker S et al (2015) Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol 17(9):1231–1240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Southwest Cancer Center, Southwest Hospital Third Military Medical University, 29 Gaotanyan Main Street, Chongqing, 400038, China

    Peiliang Geng, Xiaoxin Zhao, Juanjuan Ou, Jianjun Li, Rina Sa & Houjie Liang

Authors
  1. Peiliang Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoxin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juanjuan Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianjun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rina Sa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Houjie Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Houjie Liang.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Additional information

Peiliang Geng and Xiaoxin Zhao are co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Geng, P., Zhao, X., Ou, J. et al. TERT Genetic Mutations as Prognostic Marker in Glioma. Mol Neurobiol 54, 3665–3669 (2017). https://doi.org/10.1007/s12035-016-9930-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-016-9930-2

Keywords

Search

Navigation